| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T10 |
0-10 |
Sentence |
denotes |
BACKGROUND |
| T11 |
11-155 |
Sentence |
denotes |
Guillain-Barré syndrome (GBS) is an acute type of polyradiculoneuropathy, that occurs following immune events such as infection and vaccination. |
| T12 |
156-325 |
Sentence |
denotes |
Approximately 40%–70% of GBS cases develop following infection, and autoantibodies against glycolipids (mainly ganglioside antibodies) are detected in over 50% of cases. |
| T13 |
326-488 |
Sentence |
denotes |
The cause is generally accepted to be an abnormality in the immune process.1 2 Recently, several reports of GBS associated with SARS-CoV-2 infection have emerged. |
| T14 |
489-1061 |
Sentence |
denotes |
However, as far as we have investigated, there are still no reports in Japan.3 However, in a review of 37 cases of SARS-CoV-2-infection-related GBS, less than half of the studies investigated antiganglioside antibodies.4 Furthermore, few reports have provided details related to the antiganglioside antibody investigated, and clear descriptions of the relevant tests are available only for anti-GM1, anti-GQ1b and anti-GD1b antibodies.5–14 Most reported cases (64.8%) of SARS-CoV-2-infection-associated GBS were of the acute inflammatory demyelinating polyneuropathy type. |
| T15 |
1062-1353 |
Sentence |
denotes |
Acute motor and sensory axonal neuropathy and acute motor axonal neuropathy types were observed in 13.5% and 2.7% of cases.4 In the present report, we discuss a case of axonal-type GBS associated with SARS-CoV-2 infection, where the patient was tested for various antiganglioside antibodies. |
| T16 |
1354-1554 |
Sentence |
denotes |
Furthermore, we review the cases of SARS-CoV-2-infection-related GBS reported to date, in order to provide insight into the clinical characteristics and pathological mechanisms underlying the disease. |
| T17 |
1555-1772 |
Sentence |
denotes |
Our report also highlights the need for clinicians to remain cautious when attempting to diagnose SARS-CoV-2-infection-related GBS, and when using high-dose IV gamma globulin therapy in patients at risk of thrombosis. |
